Scholarlink

<p><i>Burkholderia pseudomallei</i>, the etiologic agent of melioidosis, is a Gram-negative bacterial pathogen that causes severe disease in humans and animals. In this study, we evaluated the safety and immunogenicity of our lead melioidosis subunit vaccine candidate in cynomolgus macaques. To accomplish this, the 6-deoxyheptan capsular polysaccharide (CPS) from <i>Burkholderia thailandensis</i> E555 was purified using a phenol-free extraction process and then conjugated to CRM197 to generate CPS-CRM197. Highly purified, His-tagless <i>B. pseudomallei</i> Hcp1 (Hcp1-TL) was also produced. Animals immunized with CPS-CRM197 combined with Hcp1-TL and adjuvanted with Alhydrogel plus CpG DNA (ODN 2006) developed robust CPS-specific IgG and opsonizing antibody responses, alongside strong Hcp1-specific IgG and measurable IFN-γ-secreting T-cell responses. Importantly, the vaccine formulations tested were well tolerated, with no adverse events after three doses. Collectively, these studies establish good manufacturing practices-compatible processes for our vaccine antigens and demonstrate the safety and immunogenicity of the subunit vaccine in non-human primates, supporting continued advancement towards a human clinical trial.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Safety and immunogenicity testing of a melioidosis subunit vaccine candidate in cynomolgus macaques

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月14日

查看全文
  • Sineenart Sengyee,
  • Caitlyn E. Orne,
  • Sarah B. Weiby,
  • Lindsey K. Schmidt,
  • Federico Urbano-Munoz,
  • Jiri Vlach,
  • Christian Heiss,
  • Parastoo Azadi,
  • Narisara Chantratita,
  • Mary N. Burtnick,
  • Paul J. Brett

摘要

Burkholderia pseudomallei, the etiologic agent of melioidosis, is a Gram-negative bacterial pathogen that causes severe disease in humans and animals. In this study, we evaluated the safety and immunogenicity of our lead melioidosis subunit vaccine candidate in cynomolgus macaques. To accomplish this, the 6-deoxyheptan capsular polysaccharide (CPS) from Burkholderia thailandensis E555 was purified using a phenol-free extraction process and then conjugated to CRM197 to generate CPS-CRM197. Highly purified, His-tagless B. pseudomallei Hcp1 (Hcp1-TL) was also produced. Animals immunized with CPS-CRM197 combined with Hcp1-TL and adjuvanted with Alhydrogel plus CpG DNA (ODN 2006) developed robust CPS-specific IgG and opsonizing antibody responses, alongside strong Hcp1-specific IgG and measurable IFN-γ-secreting T-cell responses. Importantly, the vaccine formulations tested were well tolerated, with no adverse events after three doses. Collectively, these studies establish good manufacturing practices-compatible processes for our vaccine antigens and demonstrate the safety and immunogenicity of the subunit vaccine in non-human primates, supporting continued advancement towards a human clinical trial.